INSM
Insmed IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$35.19B
P/E Ratio
—
EPS
$-6.42
Beta
1.10
52W High
$212.75
52W Low
$61.48
50-Day MA
$150.48
200-Day MA
$151.04
Dividend Yield
—
Profit Margin
-210.50%
Forward P/E
16.37
PEG Ratio
1.09
About Insmed Inc
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Fundamentals
| Revenue (TTM) | $606.42M |
| Gross Profit (TTM) | $483.49M |
| EBITDA | $-980.46M |
| Operating Margin | -94.60% |
| Return on Equity | -249.30% |
| Return on Assets | -29.00% |
| Revenue/Share (TTM) | $3.05 |
| Book Value | $3.45 |
| Price-to-Book | 47.41 |
| Price-to-Sales (TTM) | 58.03 |
| EV/Revenue | 56.38 |
| EV/EBITDA | -6.05 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 152.60% |
| Shares Outstanding | $215.85M |
| Float | $193.18M |
| % Insiders | 0.55% |
| % Institutions | 102.52% |
Analyst Ratings
Consensus ($214.79 target)
3
Strong Buy17
BuyData last updated: 4/8/2026